News
Sygnature Discovery takes pride in the accomplishments of its staff, research partnerships, and awards. Explore our latest news to learn more about company milestones, collaborations and the work of our teams.
Sygnature Discovery takes pride in the accomplishments of its staff, research partnerships, and awards. Explore our latest news to learn more about company milestones, collaborations and the work of our teams.
Filter by:
23rd April 2024
News
Sygnature Discovery goes for global industry recognition with Chief Scientific Officer hire
29th November 2023
News
First patients dosed in Phase 1a clinical trial of UCL-backed G-Quadruplex (G4) targeting treatment for solid tumors, including pancreatic cancer
13th November 2023
News
Sygnature Discovery Appoints Industry Leaders To Board Of Directors
2nd November 2023
News
Sygnature Discovery invests £3.75M in Compound Management to provide cutting-edge hit finding capabilities to pharma and biotechnology customers
10th October 2023
News
Sygnature Discovery collaborates with Axol Bioscience to utilize human iPSC-derived microglial cells in high-content imaging drug discovery screening workflows.
25th September 2023
News Targeted Protein Degradation
Sygnature Discovery and UBE Corporation successfully identify potent SHP2 degrader compounds
14th September 2023
News
Sygnature Discovery’s hit finding expertise in high demand as cardiac biotech customer, River BioMedics, receives an additional €2M seed investment
31st July 2023
News
Sygnature Discovery accelerates global growth with major North American acquisition
12th June 2023
News
Sygnature Discovery launches its in vivo LPS model to profile early-stage anti-inflammatory drugs
18th April 2023
News
Sygnature Discovery and Daewoong Pharma announce research collaboration
7th March 2023
News
New platform set to accelerate early-stage targeted protein degradation
17th January 2023
News
Sygnature Discovery completes acquisition of SB Drug Discovery to further strengthen its market-leading capabilities